Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19481966 | 1.00 | MAPK8 (0.41) | MAPK8IDH1RETKMT2AMAPT | |
| SCHEMBL19481748 | 0.93 | KMT2A (0.44) | MAPK8KMT2AMAPTUSP2LMNA | |
| SCHEMBL19481906 | 0.93 | KMT2A (0.38) | MAPK8RETKMT2AMAPTUSP2 | |
| SCHEMBL19481958 | 0.90 | KMT2A (0.41) | MAPK8RETKMT2AMAPTUSP2 | |
| SCHEMBL19481808 | 0.90 | MAPT (0.45) | KMT2AMAPTUSP2LMNANPSR1 | |
| SCHEMBL19486480 | 0.89 | HSD11B1 (0.47) | RETKMT2AMAPTUSP2LMNA | |
| SCHEMBL19481975 | 0.89 | RET (0.39) | IDH1RETTDP1RUVBL1 | |
| SCHEMBL19486349 | 0.89 | RET (0.39) | IDH1RETTDP1RUVBL1 | |
| SCHEMBL19481915 | 0.89 | RET (0.41) | IDH1RETTDP1RUVBL1 | |
| SCHEMBL25795703 | 0.89 | RET (0.41) | IDH1RETTDP1RUVBL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442977-B1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | MAPK8 443/4885IDH1 1074/4885RET 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.